Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Peng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1484-1076; OpenAlex author ID A5100395980. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 2, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 trial · 2023: 1 paper · 2024: 2 papers

Papers 6

  1. Microbiome and metabolome analysis in smoking and non-smoking pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1186/s12866-024-03688-5↗
  2. Succession of the multi-site microbiome along pancreatic ductal adenocarcinoma tumorigenesis. Co-author DOI 10.3389/fimmu.2024.1487242↗
  3. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer. Co-author DOI 10.1002/mc.23627↗
  4. MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. First author DOI 10.3892/or.2017.6036↗
  5. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. Co-author PMID 27448780↗
  6. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. First author DOI 10.1097/mpa.0b013e3181e6e398↗

Trials 1

  1. Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer Principal investigator NCT05303090↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yiqing Zhu · 2 shared papers, 2024 · strength 0.37
  2. Xiao Liang · 2 shared papers, 2024 · strength 0.37
  3. Yue Fu · 2 shared papers, 2017–2023 · strength 0.24
  4. Yi Miao · 2 shared papers, 2017–2023 · strength 0.24
  5. Xinchun Liu · 2 shared papers, 2017–2023 · strength 0.24
  6. Qiuyang Chen · 2 shared papers, 2017–2023 · strength 0.24
  7. Zhen Li · 1 shared paper, 2024 · strength 0.20
  8. Shangnan Dai · 1 shared paper, 2023 · strength 0.18
  9. Ruiguang Ma · 1 shared paper, 2024 · strength 0.17
  10. Zhen Li · 1 shared paper, 2024 · strength 0.17
  11. Yifan Wang · 1 shared paper, 2024 · strength 0.17
  12. Wentao Gao · 1 shared paper, 2017 · strength 0.07
  13. Jishu Wei · 1 shared paper, 2017 · strength 0.07
  14. Junli Wu · 1 shared paper, 2017 · strength 0.07
  15. Kuirong Jiang · 1 shared paper, 2017 · strength 0.07
  16. Zhouyu Ning · 1 shared paper, 2016 · strength 0.05
  17. Zhi Qiang Meng · 1 shared paper, 2016 · strength 0.05
  18. Weidong Shi · 1 shared paper, 2016 · strength 0.05
  19. Liping Zhuang · 1 shared paper, 2016 · strength 0.05
  20. Kun Wang · 1 shared paper, 2016 · strength 0.05
  21. Chien‐shan Cheng · 1 shared paper, 2016 · strength 0.05
  22. Jing Xie · 1 shared paper, 2016 · strength 0.05
  23. Luming Liu · 1 shared paper, 2011 · strength 0.03
  24. Zhen Chen · 1 shared paper, 2011 · strength 0.03
  25. Huaqiang Ouyang · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.